IL6 and congenital rubella syndrome: There are ongoing studies investigating the timing of tocilizumab and its efficacy in treating CRS specifically in B cell ALL (ClinicalTrials.gov number, NCT02906371); however, neither glucocorticoids nor anti IL6 therapy have been reported to significantly effect treatment response.